Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Sold by US Bancorp DE

US Bancorp DE lowered its stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 9.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 33,600 shares of the medical device company’s stock after selling 3,320 shares during the period. US Bancorp DE owned approximately 0.05% of Tandem Diabetes Care worth $1,425,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of TNDM. Vanguard Group Inc. grew its position in Tandem Diabetes Care by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 7,052,570 shares of the medical device company’s stock valued at $249,732,000 after buying an additional 30,664 shares during the last quarter. Fred Alger Management LLC boosted its holdings in shares of Tandem Diabetes Care by 45.2% in the second quarter. Fred Alger Management LLC now owns 2,174,107 shares of the medical device company’s stock valued at $87,595,000 after acquiring an additional 677,036 shares in the last quarter. Bellevue Group AG increased its stake in shares of Tandem Diabetes Care by 2.0% during the first quarter. Bellevue Group AG now owns 2,031,888 shares of the medical device company’s stock worth $71,949,000 after acquiring an additional 39,571 shares during the period. Chicago Capital LLC raised its holdings in Tandem Diabetes Care by 22.2% during the third quarter. Chicago Capital LLC now owns 1,003,147 shares of the medical device company’s stock worth $42,543,000 after purchasing an additional 182,085 shares in the last quarter. Finally, Brown Capital Management LLC lifted its position in Tandem Diabetes Care by 29.9% in the first quarter. Brown Capital Management LLC now owns 954,567 shares of the medical device company’s stock valued at $33,801,000 after purchasing an additional 219,940 shares during the period.

Analyst Upgrades and Downgrades

TNDM has been the topic of several recent analyst reports. Canaccord Genuity Group began coverage on Tandem Diabetes Care in a research report on Thursday, August 8th. They set a “buy” rating and a $57.00 target price on the stock. Royal Bank of Canada initiated coverage on Tandem Diabetes Care in a report on Wednesday, October 2nd. They set an “outperform” rating and a $65.00 price objective on the stock. The Goldman Sachs Group started coverage on Tandem Diabetes Care in a report on Friday, October 4th. They issued a “neutral” rating and a $46.00 target price for the company. Sanford C. Bernstein started coverage on shares of Tandem Diabetes Care in a research note on Wednesday. They set an “outperform” rating and a $42.00 price target on the stock. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $45.00 price objective on shares of Tandem Diabetes Care in a research note on Monday, September 23rd. Five research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $54.13.

Tandem Diabetes Care Stock Down 2.7 %

TNDM opened at $33.32 on Friday. The firm has a market cap of $2.18 billion, a P/E ratio of -15.94 and a beta of 1.36. The business’s fifty day simple moving average is $38.99 and its 200 day simple moving average is $41.82. Tandem Diabetes Care, Inc. has a 52 week low of $13.82 and a 52 week high of $53.69. The company has a quick ratio of 2.38, a current ratio of 3.05 and a debt-to-equity ratio of 1.31.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.